Stage
Other Investors | AliveLatest Abbott News
May 10, 2022
News provided by Share this article Share this article The global Optical Coherence Tomography (OCT) market size is expected to reach USD 2.16 billion by 2030 according to this new study. The report gives a detailed insight into current market dynamics and provides analysis on future market growth. Some of the important drivers driving the global demand are the growing use of the market in dentistry, cardiovascular medicine, ophthalmology, and other fields. The industry demand will be accelerated by the growing popularity of sophisticated imaging techniques in diagnostic health institutions. Furthermore, the rising frequency of eye illnesses, including glaucoma, diabetic retinopathy, among others, has boosted device use in healthcare facilities and imaging institutes. As the number of instances of these conditions rises, industry participants are turning to sophisticated technology to build enhanced imaging equipment. Regionally, the North American province dominates the global market, and is projected to continue during the projected timeline, due to the presence of major producers in the region, increased R&D activities, and growing preference for OCT among the general public. Some of the players operating in the global market include Agfa Healthcare, Alcon, Abbott Laboratories, Braun Melsungen AG, Boston Scientific Corporation, Carl Zeiss AG, Heidelberg Engineering GmbH, Danaher Corporation, Imalux Corporation, KONINKLIJKE PHILIPS N.V, NIDEK Co Ltd, Michelson Diagnostics, Nidek Co, Ltd, Novacam Technologies Inc, Optovue, Terumo Corporation, OPTOPOL Technology S.A, Thorlabs Inc, and Topcon Corporation. Intense R&D efforts characterize the industry, the launch of various unique products, and the development of revolutionary hybridization technologies, as players are doing all possible strategies to strengthen their position. Abbott released the first optical coherence tomography interactive virtual device in 2020. This will be used for cardiologists' training. Furthermore, TOPCON Canada Inc confirmed the release of 3D Maestro2 in 2019. It's a spectrum dimension optical coherence tomography device that may also be used for angiography. Key Topics Covered:
Abbott Web Traffic
Abbott Rank
Where is Abbott's headquarters?
Abbott's headquarters is located at 100 Abbott Park Road., Abbott Park.
What is Abbott's latest funding round?
Abbott's latest funding round is Other Investors.
Who are Abbott's competitors?
Competitors of Abbott include Acorai and 1 more.
You May Also Like
Vectorious Medical Technologies is developing a cardiac monitoring system for congestive heart failure patients. Vectorious technology helps physicians to help patients help themselves. Via a simple, minimally-invasive implanted device, easy-to-access data and user-friendly external home-unit; the Vectorious system increases CHF patient quality of life and reduces readmission rates.
Biofourmis discovers, develops, and delivers clinically-validated, software-based therapeutics to provide better outcomes for patients, advanced tools for clinicians to deliver personalized care, technology for pharmaceutical companies to demonstrate value, and cost-effective solutions for payers. Biofourmis has built Biovitals, a personalized, AI-powered health analytics platform that predicts clinical exacerbation in advance of a critical event, which is the backbone of its digital therapeutics product pipeline across multiple therapeutic areas, including heart failure, oncology, acute coronary syndrome, COPD, and chronic pain. The company was founded in 2015 and is based in Boston, Massachusetts.
Endotronix develops an integrated platform to provide reimbursable health management tools for patients suffering from chronic heart failure. The company's solution includes a cloud-based disease management data system and outpatient hemodynamic management with a wireless pulmonary artery sensor for early detection of worsening heart failure.
Acorai is developing the Acorai Heart Monitor, which is an AI-based medical device intended to non-invasively monitor the heart. It is based in Helsingborg, Sweden.
SMT develops and manufactures cardiac products in India. Its product portfolio includes coronary stents (drug-eluting and bare-metal), renal stents, angioplasty balloon catheters, and other cardiac accessories in India and abroad.
Bioheart (2185.HK) develops, manufactures, and sells medical devices. The company focuses on fully-absorbable coronary drug-eluting stents.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.